Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis

@article{Benn2015PositionSF,
  title={Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis},
  author={Peter Benn and Antoni Borrell and Rossa W. K. Chiu and Howard Cuckle and Lorraine Dugoff and Brigitte H. W. Faas and Susan J Gross and Tianhua Huang and Joann Johnson and Ron Maymon and Mary E. Norton and Anthony O Odibo and Peter Schielen and Kevin Spencer and David Wright and Yuval Yaron},
  journal={Prenatal Diagnosis},
  year={2015},
  volume={35},
  pages={725 - 734}
}
President President-Elect Past President Secretary Treasurer Lucas Otano MD, PhD (Argentina) Ignatia B. Van den Veyver MD (USA) Jan M.M. van Lith MD, PhD (Netherlands) Louise Wilkins-Haug MD (USA) Antoni Borrell MD, PhD (Spain) Directors Peter Benn PhD, DSc (USA) Lyn Chitty PhD (UK) Rossa Chiu (Hong Kong) Roland Devlieger MD, PhD (Belgium) Sylvie Langlois MD, CCMG (Canada) Anthony O. Odibo MD, MSCE (USA) R. Doug Wilson MD, Msc, FRCSC (Canada) Yuval Yaron MD (Israel) Diana W. Bianchi MD, ex… Expand
International Society for Prenatal Diagnosis Position Statement: cell free (cf)DNA screening for Down syndrome in multiple pregnancies
Department of Pathology and Laboratory Medicine, Women & Infants Hospital and the Alpert Medical School at Brown University, Providence, Rhode Island Department of Chemical Pathology, The ChineseExpand
Current controversies in prenatal diagnosis 1: should NIPT routinely include microdeletions/microduplications?
TLDR
This written debate summarizes the oral presentations made at the 2015 International Society for Prenatal Diagnosis meeting in Washington, DC, USA. Expand
Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics
TLDR
This statement sets forth a new framework for NIPS that is supported by information from validation and clinical utility studies, and Laboratories are encouraged to meet the needs of providers and their patients by delivering meaningful screening reports and to engage in education. Expand
Impact of the increased adoption of prenatal cfDNA screening on non‐profit patient advocacy organizations in the United States
TLDR
Concerns and challenges raised by prenatal cell‐free DNA screening have resulted in larger demands upon PAGs from concerned patients receiving prenatal cfDNA screening results, and suggestions for addressing these challenges are put forward. Expand
Screening for Fetal Abnormalities
TLDR
This review summarises the already well established screening methods for fetal abnormalities and also introduces newer emerging techniques. Expand
Positive Attitudes towards Non-Invasive Prenatal Testing (NIPT) in a Swedish Cohort of 1,003 Pregnant Women
TLDR
An increased understanding of pregnant women’s awareness, attitudes, preferences for risk information and decision-making concerning prenatal examinations with emphasis on NIPT is gained, before its introduction into Swedish healthcare. Expand
Ethical and practical challenges in providing noninvasive prenatal testing for chromosome abnormalities: an update
TLDR
It is believed that the same ethical and legal principles that were considered in the justification of conventional prenatal screening can be used to assess the appropriateness of additional NIPT applications. Expand
Current controversies in prenatal diagnosis: Expanded NIPT that includes conditions other than trisomies 13, 18, and 21 should be offered
TLDR
The debate presented here - Expanded NIPT that includes conditions other than trisomies 13, 18, and 21 should be offered - will see the pros and cons of screening for a wider range of chromosomal problems. Expand
Are the selected criteria of NIPT reasonable ? New point of view from the analysis of the Down syndrome characteristics
Aims: To discuss the selected criteria of NIPT according to the data of Down syndrome (DS) characteristics. Methods: In this multicenter study, we collected a total of 332 cases of DS in threeExpand
Non-Invasive Prenatal Tests (NIPT): Review Article
TLDR
The utilization of NIPT/S as a primary Down syndrome screening test should not replace the 11–13 weeks scan and the location rate is still unsure, and the positive prescient worth is required to be lower. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
DNA sequencing versus standard prenatal aneuploidy screening.
TLDR
From the Mother Infant Research Institute, Tufts Medical Center and Tufts University School of Medicine, Boston (D.W.C., P.I.D., K.L.O., R.P.R., A.F.S.) — all in California; and Colorado Permanente Medical Group, Denver. Expand
Summary of the ISPD Preconference Day, June 3, 2012, Miami Beach
Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO, USA MolecularExpand
Non-Invasive Prenatal Chromosomal Aneuploidy Testing - Clinical Experience: 100,000 Clinical Samples
TLDR
The accuracy and NIPT assay positivity rate are as predicted by clinical validations and the test demonstrates improvement in the current standard of care. Expand
Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease
TLDR
This data indicates that pre- and post-menopausal women who have had vaginal or laparoscopic Caesarean sections are more likely to have low levels of prolapse preoperatively than those who undergo surgery. Expand
Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes.
TLDR
SNP-based noninvasive prenatal microdeletion screening is highly accurate and should be considered for the general pregnant population because clinically relevant microdeletes and duplications occur in >1% of pregnancies. Expand
Non‐invasive prenatal testing – it's all a matter of timing
  • Y. Zalel
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2015
TLDR
The timing of offering NIPT to women at 10 weeks of gestation is challenged, as six women attended for an early anomaly scan, at a mean gestational age of 15 + 1 weeks, after a normal NipT result. Expand
Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18.
TLDR
Ch Chromosome-selective sequencing of cell-free DNA and application of an individualized risk algorithm is effective in the detection of fetal T21 and T18. Expand
DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study
TLDR
Measurement of circulating cell-free DNA in maternal plasma DNA detects nearly all cases of Down syndrome at a very low false-positive rate, and can substantially reduce the need for invasive diagnostic procedures and attendant procedure-related fetal losses. Expand
Cell-free DNA screening for fetal aneuploidy as a clinical service.
TLDR
Non-invasive prenatal testing (NIPT) through the analysis of cell free (cf)DNA is revolutionizing prenatal screening for fetal aneuploidy, with effectiveness for the common autosomal trisomies far exceeds that of conventional screening. Expand
Non‐invasive prenatal testing for aneuploidy: current status and future prospects
  • P. Benn, H. Cuckle, E. Pergament
  • Medicine
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2013
TLDR
Non‐invasive prenatal testing for aneuploidy using cell‐free DNA in maternal plasma is revolutionizing prenatal screening and diagnosis and providing adequate prenatal counseling poses a substantial challenge given the broad range of prenatal testing options now available. Expand
...
1
2
3
4
5
...